TuHURA Biosciences (HURA) Amortization - Deferred Charges (2020 - 2021)
TuHURA Biosciences' (HURA) quarterly Amortization - Deferred Charges came in at $20000.0 in Q2 2021, down 13.04% quarter-over-quarter from $23000.0 in Q1 2021.
TuHURA Biosciences (HURA) Amortization - Deferred Charges (2020 - 2021) Analysis & Trends
TuHURA Biosciences' Amortization - Deferred Charges history runs 2 years deep, the most recent figure standing at $20000.0 for Q2 2021.
- On a quarterly basis, Amortization - Deferred Charges changed N/A year-over-year to $20000.0 in Q2 2021; TTM through Jun 2021 was $95000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $94000.0, changed N/A from the prior year.
- Amortization - Deferred Charges slipped to $20000.0 in Q2 2021 per HURA's latest filing, from $23000.0 in the prior quarter.
- Across five years, Amortization - Deferred Charges topped out at $27000.0 in Q3 2020 and bottomed at $20000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortization - Deferred Charges (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | TuHURA Biosciences | 132.62 Mn | 132.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 20,000.00 |
| Jun 30, 2021 | 20,000.00 |
| Mar 31, 2021 | 23,000.00 |
| Mar 31, 2021 | 23,000.00 |
| Dec 31, 2020 | 25,000.00 |
| Dec 31, 2020 | 25,000.00 |
| Sep 30, 2020 | 27,000.00 |
| Sep 30, 2020 | 27,000.00 |